<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965844</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AG)539/2020</org_study_id>
    <nct_id>NCT04965844</nct_id>
  </id_info>
  <brief_title>Closed-loop Oxygen Control for High Flow Nasal Therapy</brief_title>
  <acronym>HILOOP</acronym>
  <official_title>Safety and Efficacy of a Closed-loop Oxygen Control for High Flow Nasal Therapy in ICU Patients: a Randomized Cross-over Study (The HILOOP Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with acute hypoxemic respiratory failure (AHRF), High Flow Nasal Therapy (HFNT)&#xD;
      improves oxygenation, tolerance, and decrease work of breathing as compared to standard&#xD;
      oxygen therapy by facemask. Current guidelines recommend adjusting oxygen flow rates to keep&#xD;
      the oxygen saturation measured by pulse oximetry (SpO2) in the target range and avoid&#xD;
      hypoxemia and hyperoxemia. The hypothesis of the study is that closed loop oxygen control&#xD;
      increases the time spent within clinically targeted SpO2 ranges and decreases the time spent&#xD;
      outside clinical target SpO2 ranges as compared to manual oxygen control in ICU patients&#xD;
      treated with HFNT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Actual">August 10, 2021</completion_date>
  <primary_completion_date type="Actual">August 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time spent in optimal SpO2 range</measure>
    <time_frame>4 hours</time_frame>
    <description>The optimal SpO2 range will be defined according to the SpO2 targets determined by the clinician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of time spent in sub-optimal SpO2 range</measure>
    <time_frame>4 hours</time_frame>
    <description>SpO2 values outside the optimal range but still within an acceptable limit (2-3 percent above and below the optimal range)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time spent out of range</measure>
    <time_frame>4 hours</time_frame>
    <description>Above or below the suboptimal limits specified at the begginning of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time with SpO2 signal available</measure>
    <time_frame>4 hours</time_frame>
    <description>Time with SpO2 signal available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean SpO2/FiO2</measure>
    <time_frame>4 hours</time_frame>
    <description>Mean oxygenation value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROX index</measure>
    <time_frame>4 hours</time_frame>
    <description>Is a predictor of HFNT success/failure defined as (SpO2/FiO2)/respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time with SpO2 below 88 and 85 percent</measure>
    <time_frame>4 hours</time_frame>
    <description>Duration of time with SpO2 &lt;85 percent and &lt;88 percent, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of events with SpO2 below 88 and 85 percent</measure>
    <time_frame>4 hours</time_frame>
    <description>Frequency of SpO2 decreases &lt;85 percent and &lt;88 percent, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean FiO2</measure>
    <time_frame>4 hours</time_frame>
    <description>Mean fraction of inspired oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time with FiO2 below 40 percent, 60 percent and 100 percent</measure>
    <time_frame>4 hours</time_frame>
    <description>Percentage of time that FiO2 is &lt;40 percent, 60 percent and 100 percent, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of manual adjustments</measure>
    <time_frame>4 hours</time_frame>
    <description>Frequency of manual adjustments of FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of alarms</measure>
    <time_frame>4 hours</time_frame>
    <description>Frequency of alarms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>High Flow Nasal Cannula</condition>
  <condition>Oxygen Therapy</condition>
  <condition>Hypoxemia</condition>
  <condition>Hyperoxemia</condition>
  <condition>Acute Respiratory Failure</condition>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>Oxygen close-loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four hours period where the fraction of inspired oxygen delivered will be automatically titrated based on SpO2 values.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual FiO2 adjustment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four hours period where the fraction of inspired oxygen delivered will be manually adjusted by the healthcare personnel based on SpO2 values.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxygen close-loop</intervention_name>
    <description>The Automatic FiO2 option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the Oxygen setting to keep the patient's SpO2 in the target range.</description>
    <arm_group_label>Oxygen close-loop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Manual FiO2 adjustment according to SpO2 values</description>
    <arm_group_label>Manual FiO2 adjustment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (&gt;17yo) patients admitted to the ICU treated with HFNT for at least 8h&#xD;
&#xD;
          -  Requiring FiO2 ≥ 30% to keep SpO2 in the target ranges defined by the clinician&#xD;
&#xD;
          -  Written informed consent signed and dated by the patient or one relative in case that&#xD;
             the patient is unable to consent, after full explanation of the study by the&#xD;
             investigator and prior to study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with indication for immediate continuous positive airway pressure (CPAP),&#xD;
             noninvasive ventilation (NIV), or invasive mechanical ventilation&#xD;
&#xD;
          -  Hemodynamic instability defined as a need of continuous infusion of epinephrine or&#xD;
             norepinephrine &gt; 1 mg/h&#xD;
&#xD;
          -  Low quality on the SpO2 measurement using finger and ear sensor (quality index below&#xD;
             60% on the Massimo SpO2 sensor, which is displayed by a red or orange colour bar)&#xD;
&#xD;
          -  Severe acidosis (pH ≤ 7.30)&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Patients deemed at high risk for need of mechanical ventilation within the next 8&#xD;
             hours&#xD;
&#xD;
          -  Chronic or acute dyshemoglobinemia: methemoglobin, carbon monoxide (CO) poisoning,&#xD;
             sickle cell disease&#xD;
&#xD;
          -  Tracheotomised patient&#xD;
&#xD;
          -  Formalized ethical decision to withhold or withdraw life support&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Patient deprived of liberties&#xD;
&#xD;
          -  Patient included in another interventional research study under consent&#xD;
&#xD;
          -  Patient already enrolled in the present study in a previous episode of acute&#xD;
             respiratory failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <reference>
    <citation>L'Her E, Dias P, Gouillou M, Riou A, Souquiere L, Paleiron N, Archambault P, Bouchard PA, Lellouche F. Automatic versus manual oxygen administration in the emergency department. Eur Respir J. 2017 Jul 20;50(1). pii: 1602552. doi: 10.1183/13993003.02552-2016. Print 2017 Jul.</citation>
    <PMID>28729473</PMID>
  </reference>
  <reference>
    <citation>Helmerhorst HJ, Roos-Blom MJ, van Westerloo DJ, de Jonge E. Association Between Arterial Hyperoxia and Outcome in Subsets of Critical Illness: A Systematic Review, Meta-Analysis, and Meta-Regression of Cohort Studies. Crit Care Med. 2015 Jul;43(7):1508-19. doi: 10.1097/CCM.0000000000000998. Review.</citation>
    <PMID>25855899</PMID>
  </reference>
  <reference>
    <citation>Arnal JM, Garnero A, Novotni D, Corno G, Donati SY, Demory D, Quintana G, Ducros L, Laubscher T, Durand-Gasselin J. Closed loop ventilation mode in Intensive Care Unit: a randomized controlled clinical trial comparing the numbers of manual ventilator setting changes. Minerva Anestesiol. 2018 Jan;84(1):58-67. doi: 10.23736/S0375-9393.17.11963-2. Epub 2017 Jul 5.</citation>
    <PMID>28679200</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High flow nasal cannula</keyword>
  <keyword>Nasal high flow</keyword>
  <keyword>Oxygen close-loop</keyword>
  <keyword>Hypoxemia</keyword>
  <keyword>Hyperoxemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

